The FAST III trial has found that angiography-guided treatment for intermediate coronary artery blockages performs as well as the more invasive pressure-wire method when measuring death, heart attack, or need for further treatment.
What the Trial Found
A large clinical trial published by the New England Journal of Medicine has found that a standard imaging technique used to assess partially blocked heart arteries produces outcomes no worse than a more specialist pressure-wire approach — a finding that could influence how cardiologists across the country guide treatment decisions.
The FAST III trial examined patients with intermediate coronary lesions, which are partial blockages in the arteries supplying the heart that sit in a grey zone — neither clearly severe enough to treat immediately nor clearly safe to leave alone. Deciding what to do with these lesions has long been a point of clinical debate.
According to the trial results, angiography-guided revascularisation — using X-ray imaging with contrast dye to visualise the arteries — was noninferior to pressure-wire–based guidance. The primary measure used to judge outcomes covered three events: death, myocardial infarction (a heart attack), and the need for further revascularisation procedures.
Non-inferiority, in clinical trial terms, means the angiography approach did not perform meaningfully worse than the comparator. It does not necessarily mean the two are identical, but that the difference falls within an acceptable margin.
Why This Matters Clinically
Pressure-wire guidance — often delivered through a technique called fractional flow reserve, or FFR — involves threading a thin wire into the coronary artery to measure blood pressure and flow directly. It is considered the gold standard for assessing intermediate lesions but requires additional equipment, expertise, and procedural time.
Angiography, by contrast, is already the baseline tool used in virtually every cardiac catheterisation procedure. If angiography alone can guide decisions just as effectively, that has practical consequences for how catheter labs are run and how quickly patients move through assessment.
The New England Journal of Medicine posted the findings directly, alongside a research summary for wider reading.
The Limits of What We Know
The tweet from the NEJM account does not detail the trial’s sample size, the length of follow-up, or which patient subgroups were studied. Those details sit within the full published paper. Readers seeking the complete methodology and results would need to access the journal directly.
No UK-specific commentary, NHS England response, or British Cardiovascular Society statement has been issued in connection with this publication at the time of writing.
—
Source: @NEJM
Key Takeaways
- The FAST III trial found angiography-guided revascularisation was noninferior to pressure-wire–based guidance for intermediate coronary lesions
- The primary outcome measured death, myocardial infarction, or need for further revascularisation
- Full results and a research summary have been published by the New England Journal of Medicine
What This Means for Kent Residents
Patients in Kent who have undergone or are awaiting cardiac catheterisation procedures for suspected coronary artery disease should not change or delay any planned treatment on the basis of this research alone. Any questions about how intermediate coronary lesions are assessed or treated should be directed to a GP or the referring cardiology team at hospitals including Maidstone and Tunbridge Wells NHS Trust or East Kent Hospitals University NHS Foundation Trust. For urgent cardiac concerns, call NHS 111; in an emergency, always dial 999.